The Summer 2020 Issue of Nutraceuticals Now is now available.
Excerpts of the following articles are available on this website:
To download a PDF of this issue, please subscribe to Nutraceuticals Now or login to your account.
Urinary Tract Infection (UTI) is the most common infection among women: it has been shown that nearly one in three women will have had at least one episode of UTI requiring antimicrobial therapy before they reach the age of 24. Moreover, UTI is characterised by a high reoccurrence rate: it has been estimated that nearly half of the women who have had UTI will experience another one within 12 months. The main causative agent is Escherichia coli (E. coli), normally present in the colon. Symptoms are both uncomfortable and debilitating and associated healthcare costs are high.
UTIs are traditionally treated with antibiotics, however, scientists believe that antibiotic treatments can disrupt the natural occurrence of beneficial bacteria in the body, leading to higher recurrence of UTI. Furthermore, repeated antibiotic treatments can give rise to antibiotic-resistant strains of harmful bacteria. Cranberries are widely documented for their preventive effect against UTI due to their unique anti-adhesion activity against pathogenic bacteria, which is linked to the presence of key phytochemicals: proanthocyanidins (PACs). Today, there is a growing demand for high quality cranberry extracts with high amount of proanthocyanidins to support urinary tract health. Lallemand Health Ingredients, in partnership with leading cranberry expert Decas Botanical Synergies have joined their marketing and R&D efforts to develop high quality cranberry ingredients solutions aimed at meeting this demand.
This article is available in full in the Spring 2010 issue of Nutraceuticals Now